Profile
| Metric | Value |
|---|---|
| Full Name | Akero Therapeutics, Inc. |
| Ticker | NASDAQ: AKRO |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | akerotx.com |
| Employees | 74 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $54.65 | |
| Price, 1D Change | - | |
| Market Cap | $4B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.56 | |
| Revenue | $0 | |
| Revenue, 1Y Change | 0.00% | |
| EPS | -$3.75 | |
| EPS, 1Y Change | -30.05% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$3.75 | |
| EPS Estimate | -$3.94 | |
| EPS Est. Change | -4.81% | |
| Revenue | $0.00 | |
| Revenue Estimate | - | |
| Revenue Est. Change | - | |
| Current Price | $54.65 | |
| Price Target | - | $57.00 |
| Price Tgt. Change | - | +4.30% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$2.84 | -$2.89 | -1.65% | |
| -$3.95 | -$3.75 | +4.99% | |
| -$3.94 | N/A | -4.81% | |
| -$4.22 | N/A | -12.45% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| - | $0.00 | - | |
| - | $0.00 | - | |
| - | N/A | - | |
| - | N/A | - |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +97.72% | |
| Price, 3Y | +21.93% | |
| Market Cap, 1Y | +124.85% | |
| Market Cap, 3Y | +114.17% | |
| Revenue, 1Y | 0.00% | |
| Revenue, 3Y | 0.00% | |
| EPS, 1Y | -30.05% | |
| EPS, 3Y | -29.75% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $54.65 | |
| SMA 200 | $48.19 | |
| SMA 200 vs Price | -11.82% | |
| SMA 50 | $53.06 | |
| SMA 50 vs Price | -2.91% | |
| Beta | 0.56 | |
| ATR | $0.30 | |
| 14-Day RSI | 69.09 | |
| 10-Day Volatility | 2.40% | |
| 1-Year Volatility | 111.94% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $0.00 | |
| EPS | -$3.75 | |
| Gross Profit | -$18.00K | |
| - | ||
| Operating Profit | -$285.42M | |
| - | ||
| Net Income | -$252.06M | |
| - | ||
| EBITDA | -$285.41M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.05 | |
| Current Ratio | 19.38 | |
| Quick Ratio | 19.38 | |
| - | ||
| - | ||
| Altman Z-Score | 34.14 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | - | |
| PB Ratio | 4.70 | |
| EV/EBITDA | -11.40 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $750.11M | |
| Cash & Equivalents | $340.24M | |
| Total Assets | $825.89M | |
| Current Assets | $770.38M | |
| Total Liabilities | $75.77M | |
| Current Liabilities | $39.75M | |
| Total Debt | $36.12M | |
| Short Term Debt | $291.00K | |
| Accounts Payable | $9.03M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $252.06M | |
| Operating Expenses | $285.41M | |
| Cost Of Goods Sold | $18.00K | |
| SG&A | $0.00 | |
| D&A | $18.00K | |
| Interest Expense | $0.00 | |
| Income Tax | $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$230.11M | |
| CFI | -$109.71M | |
| CFF | $445.85M | |
| Capex | $0.00 | |
| Free Cash Flow | -$230.11M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Wolfe Research | → | |
| HC Wainwright & Co. | → | |
| Jefferies | → | |
| Canaccord Genuity | → | |
| TD Cowen | ||
| B of A Securities | → | |
| Citigroup | → | |
| HC Wainwright & Co. | → | |
| UBS | → | |
| B of A Securities | → |
Analyst sentiment
Institutional ownership
Screeners with AKRO
Data Sources & References
- AKRO Official Website akerotx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1744659/000119312525272569/0001193125-25-272569-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1744659/000095017025029514/0000950170-25-029514-index.htm
- AKRO Profile on Yahoo Finance finance.yahoo.com/quote/AKRO
- AKRO Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/akro
FAQ
What is the ticker symbol for Akero Therapeutics, Inc.?
The ticker symbol for Akero Therapeutics, Inc. is NASDAQ:AKRO
Does Akero Therapeutics, Inc. pay dividends?
No, Akero Therapeutics, Inc. does not pay dividends
What sector is Akero Therapeutics, Inc. in?
Akero Therapeutics, Inc. is in the Healthcare sector
What industry is Akero Therapeutics, Inc. in?
Akero Therapeutics, Inc. is in the Biotechnology industry
What country is Akero Therapeutics, Inc. based in?
Akero Therapeutics, Inc. is headquartered in United States
When did Akero Therapeutics, Inc. go public?
Akero Therapeutics, Inc. initial public offering (IPO) was on June 20, 2019
Is Akero Therapeutics, Inc. in the S&P 500?
No, Akero Therapeutics, Inc. is not included in the S&P 500 index
Is Akero Therapeutics, Inc. in the NASDAQ 100?
No, Akero Therapeutics, Inc. is not included in the NASDAQ 100 index
Is Akero Therapeutics, Inc. in the Dow Jones?
No, Akero Therapeutics, Inc. is not included in the Dow Jones index
When was Akero Therapeutics, Inc. last earnings report?
Akero Therapeutics, Inc.'s most recent earnings report was on November 10, 2025
When does Akero Therapeutics, Inc. report earnings?
The next expected earnings date for Akero Therapeutics, Inc. is February 27, 2026